Advertisement

Evaluation of the Blood Compatibility of Materials, Cells, and Tissues: Basic Concepts, Test Models, and Practical Guidelines

  • Kristina N. Ekdahl
  • Jaan Hong
  • Osama A. Hamad
  • Rolf Larsson
  • Bo Nilsson
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 735)

Abstract

Medicine today uses a wide range of biomaterials, most of which make contact with blood permanently or transiently upon implantation. Contact between blood and nonbiological materials or cells or tissue of nonhematologic origin initiates activation of the cascade systems (complement, contact activation/coagulation) of the blood, which induces platelet and leukocyte activation.

Although substantial progress regarding biocompatibility has been made, many materials and medical treatment procedures are still associated with severe side effects. Therefore, there is a great need for adequate models and guidelines for evaluating the blood compatibility of biomaterials. Due to the substantial amount of cross talk between the different cascade systems and cell populations in the blood, it is advisable to use an intact system for evaluation.

Here, we describe three such in vitro models for the evaluation of the biocompatibility of materials and therapeutic cells and tissues. The use of different anticoagulants and specific inhibitors in order to be able to dissect interactions between the different cascade systems and cells of the blood is discussed. In addition, we describe two clinically relevant medical treatment modalities, the integration of titanium implants and transplantation of islets of Langerhans to patients with type 1 diabetes, whose mechanisms of action we have addressed using these in vitro models.

Keywords

Tissue Factor Blood Compatibility Cascade System Therapeutic Cell High Molecular Weight Kininogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was supported by grants from the Swedish Research Council (VR) 2009–4675, 2009–4462, the Swedish Research Council, and the Swedish Research Council/SSF/Vinnova contract grant number 60761701 and by faculty grants from the Linnæus University. Reagents for preparing heparin-coated surfaces were obtained from Corline Systems AB. We thank Dr. Deborah McClellan for excellent editorial assistance and Mr. Hans Nilsson for preparing the illustrations in Fig. 18.1.

Conflict of Interest StatementThe author Professor R. Larsson is an employee of Corline Systems AB, Uppsala, Sweden. None of the other authors has conflicts of interest.

References

  1. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B et al (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185(9):5628–5636PubMedCentralPubMedCrossRefGoogle Scholar
  2. Andersson J, Ekdahl KN, Larsson R, Nilsson UR, Nilsson B (2002) C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunol 168(11):5786–5791PubMedCrossRefGoogle Scholar
  3. Andersson J, Sanchez J, Ekdahl KN, Elgue G, Nilsson B, Larsson R (2003) Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A 67(2):458–466PubMedCrossRefGoogle Scholar
  4. Andersson J, Ekdahl KN, Lambris JD, Nilsson B (2005a) Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials 26(13):1477–1485PubMedCrossRefGoogle Scholar
  5. Andersson M, Andersson J, Sellborn A, Berglin M, Nilsson B, Elwing H (2005b) Quartz crystal microbalance-with dissipation monitoring (QCM-D) for real time measurements of blood coagulation density and immune complement activation on artificial surfaces. Biosens Bioelectron 21(1):79–86PubMedCrossRefGoogle Scholar
  6. Arima Y, Toda M, Iwata H (2011) Surface plasmon resonance in monitoring of complement activation on biomaterials. Adv Drug Deliv Rev 63:988–999PubMedCrossRefGoogle Scholar
  7. Attanasio M, Gori AM, Giusti B, Pepe G, Comeglio P, Brunelli T et al (1998) Cytokine gene expression in human LPS- and IFN gamma-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 79(5):959–962PubMedGoogle Scholar
  8. Bäck J, Huber-Lang M, Elgue G, Kalbitz M, Sanchez J, Ekdahl KN et al (2009) Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. Biomaterials 30(34):6573–6580PubMedCrossRefGoogle Scholar
  9. Bäck J, Sanchez J, Elgue G, Ekdahl KN, Nilsson B (2010) Activated human platelets induce factor XIIa-mediated contact activation. Biochem Biophys Res Commun 391(1):11–17PubMedCrossRefGoogle Scholar
  10. Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H et al (1999) Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 48(10):1907–1914PubMedCrossRefGoogle Scholar
  11. Bennet W, Sundberg B, Elgue G, Larsson R, Korsgren O, Nilsson B (2001) A new in vitro model for the study of pig-to-human vascular hyperacute rejection. Xenotransplantation 8(3):176–184PubMedCrossRefGoogle Scholar
  12. Berglin M, Pinori E, Sellborn A, Andersson M, Hulander M, Elwing H (2009) Fibrinogen adsorption and conformational change on model polymers: novel aspects of mutual molecular rearrangement. Langmuir 25(10):5602–5608PubMedCrossRefGoogle Scholar
  13. Bexborn F, Engberg AE, Sandholm K, Mollnes TE, Hong J, Nilsson Ekdahl K (2009) Hirudin versus heparin for use in whole blood in vitro biocompatibility models. J Biomed Mater Res A 89(4):951–959PubMedCrossRefGoogle Scholar
  14. Bogdanov V, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y (2003) Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9(4):458–462PubMedCrossRefGoogle Scholar
  15. Cabric S, Sanchez J, Lundgren T, Foss A, Felldin M, Kallen R et al (2007) Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 56(8):2008–2015PubMedCrossRefGoogle Scholar
  16. Cabric S, Eich T, Sanchez J, Nilsson B, Korsgren O, Larsson R (2008) A new method for incorporating functional heparin onto the surface of islets of Langerhans. Tissue Eng C Methods 14(2):141–147CrossRefGoogle Scholar
  17. Chang JY (1983) The functional domain of hirudin, a thrombin-specific inhibitor. FEBS Lett 164(2):307–313PubMedCrossRefGoogle Scholar
  18. Christensen K, Larsson R, Emanuelsson H, Elgue G, Larsson A (2001) Heparin coating of the stent graft—effects on platelets, coagulation and complement activation. Biomaterials 22(4):349–355PubMedCrossRefGoogle Scholar
  19. Christensen K, Larsson R, Emanuelsson H, Elgue G, Larsson A (2006) Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents. Platelets 17(5):318–327PubMedCrossRefGoogle Scholar
  20. Distelmaier K, Adlbrecht C, Jakowitsch J, Winkler S, Dunkler D, Gerner C et al (2009) Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 102(3):564–572PubMedGoogle Scholar
  21. Ekdahl KN, Nilsson B, Pekna M, Nilsson UR (1992) Generation of iC3 at the interface between blood and gas. Scand J Immunol 35(1):85–91CrossRefGoogle Scholar
  22. Ekdahl KN, Lambris JD, Elwing H, Ricklin D, Nilsson PH, Teramura Y et al (2011) Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv Drug Deliv Rev 63(12):1042–1050PubMedCentralPubMedCrossRefGoogle Scholar
  23. Engberg AE, Rosengren-Holmberg JP, Chen H, Nilsson B, Lambris JD, Nicholls IA et al (2011) Blood protein-polymer adsorption: implications for understanding complement-mediated hemoincompatibility. J Biomed Mater Res A 94A:74–84CrossRefGoogle Scholar
  24. Engstad CS, Gutteberg TJ, Osterud B (1997) Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost 77(4):690–696PubMedGoogle Scholar
  25. Ettelaie C, Fountain D, Collier M, Elkeeb A, Xiao Y, Maraveyas A (2011) Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB. Biochim Biophys Acta 1812(12):1591–1600PubMedCrossRefGoogle Scholar
  26. Fink H, Hong J, Drotz K, Risberg B, Sanchez J, Sellborn A (2011) An in vitro study of blood compatibility of vascular grafts made of bacterial cellulose in comparison with conventionally-used graft materials. J Biomed Mater Res A [Epub ahead of print]Google Scholar
  27. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP (1983) Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 71(5):1450–1456PubMedCentralPubMedCrossRefGoogle Scholar
  28. Gong J, Larsson R, Ekdahl KN, Mollnes TE, Nilsson U, Nilsson B (1996) Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol 16(4):222–229PubMedCrossRefGoogle Scholar
  29. Gorbet MB, Sefton MV (2004) Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 25(26):5681–5703PubMedCrossRefGoogle Scholar
  30. Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D et al (1999) Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 81(4):589–593PubMedGoogle Scholar
  31. Grabowski E (1990) Platelet aggregation in flowing blood at a site of injury to an endothelial cell monolayer: quantitation and real-time imaging with the TAB monoclonal antibody. Blood 75(2):390–398PubMedGoogle Scholar
  32. Grabowski E, Curran M, Van Cott E (2012) Assessment of a cohort of primarily pediatric patients with a presumptive diagnosis of type 1 von Willebrand disease with a novel high shear rate, non-citrated blood flow device. Thromb Res [Epub ahead of print]Google Scholar
  33. Gulla K, Gupta K, Krarup A, Gal P, Schwaeble W, Sim R et al (2010) Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 129(4):482–495PubMedCentralPubMedCrossRefGoogle Scholar
  34. Gustafson EK, Elgue G, Hughes RD, Mitry RR, Sanchez J, Haglund U et al (2011) The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation 91(6):632–638PubMedCrossRefGoogle Scholar
  35. Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, Lambris JD et al (2008) Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 6(8):1413–1421PubMedCentralPubMedCrossRefGoogle Scholar
  36. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, Nilsson B (2010a) Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 185(5):2686–2692CrossRefGoogle Scholar
  37. Hamad O, Nilsson P, Lasaosa M, Ricklin D, Lambris J, Nilsson B et al (2010b) Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One 5(6):e12889PubMedCentralPubMedCrossRefGoogle Scholar
  38. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE (2004) The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 138(3):439–446PubMedCentralPubMedCrossRefGoogle Scholar
  39. Hess K, Alzahran SH, Mathai M, Schroeder V, Carter A, Howell G et al (2011) A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia [Epub ahead of print]Google Scholar
  40. Hojima Y, Pierce J, Pisano J (1980) Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res 20:149–162PubMedCrossRefGoogle Scholar
  41. Hong J, Nilsson Ekdahl K, Reynolds H, Larsson R, Nilsson B (1999a) A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. Biomaterials 20(7):603–611PubMedCrossRefGoogle Scholar
  42. Hong J, Andersson J, Ekdahl KN, Elgue G, Axen N, Larsson R et al (1999b) Titanium is a highly thrombogenic biomaterial: possible implications for osteogenesis. Thromb Haemost 82(1):58–64PubMedGoogle Scholar
  43. Hong J, Larsson A, Ekdahl KN, Elgue G, Larsson R, Nilsson B (2001) Contact between a polymer and whole blood: sequence of events leading to thrombin generation. J Lab Clin Med 138(2):139–145PubMedCrossRefGoogle Scholar
  44. Hong J, Azens A, Ekdahl K, Granqvist CG, Nilsson B (2005) Material-specific thrombin generation following contact between metal surfaces and whole blood. Biomaterials 26:1397–1403PubMedCrossRefGoogle Scholar
  45. Hong J, Kurt S, Thor A (2011) A hydrophilic dental implant surface exhibit thrombogenic properties in vitro. Clin Implant Dent Relat Res [Epub ahead of print]Google Scholar
  46. Howes J, Richardson V, Smith K, Schroeder V, Somani R, Shore A et al (2012) Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res [Epub ahead of print]Google Scholar
  47. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR et al (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12(6):682–687PubMedCrossRefGoogle Scholar
  48. Hussaini B, Treanor P, Healey N, Tilahun D, Srey R, Lu X et al (2009) Evaluation of blood components exposed to coated arterial filters in extracorporeal circuits. Perfusion 24(5):317–323PubMedCrossRefGoogle Scholar
  49. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y (1997) C5a induces tissue factor activity on endothelial cells. Thromb Haemost 77(2):394–398PubMedGoogle Scholar
  50. Johansson U, Olsson A, Gabrielsson S, Nilsson B, Korsgren O (2003) Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun 308(3):474–479PubMedCrossRefGoogle Scholar
  51. Johansson H, Lukinius A, Moberg L, Lundgren T, Berne C, Foss A et al (2005) Tissue factor produced by endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 54(6):1755–1762PubMedCrossRefGoogle Scholar
  52. Johnell M, Larsson R, Siegbahn A (2005) The influence of different heparin surface concentrations and antithrombin-binding capacity on inflammation and coagulation. Biomaterials 26(14):1731–1739PubMedCrossRefGoogle Scholar
  53. Jokiranta TS, Westin J, Nilsson B, Ekdahl KN, Hellwage J, Gordon DL et al (2001) Complement C3b interactions with its ligands measured by Biacore equipment: a new powerful and informative method. Int Immunopharmacol 1:495–506PubMedCrossRefGoogle Scholar
  54. Katragadda M, Lambris JD (2006) Expression of compstatin in Escherichia coli: incorporation of unnatural amino acids enhances its activity. Protein Expr Purif 47(1):289–295PubMedCrossRefGoogle Scholar
  55. Keil L, Jimenez E, Guma M, Reyes M, Liguori C, DeBari V (1995) Biphasic response of complement to heparin: fluid-phase generation of neoantigens in human serum and in a reconstituted alternative pathway amplification cycle. Am J Hematol 50(4):254–262PubMedCrossRefGoogle Scholar
  56. Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, Mitroulis I et al (2010) Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116(4):631–639PubMedCentralPubMedCrossRefGoogle Scholar
  57. Krarup A, Gulla C, Gál P, Hajela K, Sim R (2008) The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta 1784:1294–1300PubMedCrossRefGoogle Scholar
  58. Lachmann PJ, Pangburn MK, Oldroyd RG (1982) Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med 156(1):205–216PubMedCrossRefGoogle Scholar
  59. Lappegård K, Fung M, Bergseth G, Riesenfeld J, Lambris J, Videm V et al (2004) Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg 77(3):932–941PubMedCrossRefGoogle Scholar
  60. Lappegård K, Riesenfeld J, Brekke O, Bergseth G, Lambris J, Mollnes T (2005) Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. Ann Thorac Surg 79(3):917–923PubMedCrossRefGoogle Scholar
  61. Lappegård KT, Bergseth G, Riesenfeld J, Pharo A, Magotti P, Lambris JD et al (2008) The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A 87(1):129–135PubMedCentralPubMedCrossRefGoogle Scholar
  62. Larsson R, Elgue G, Larsson A, Ekdahl KN, Nilsson UR, Nilsson B (1997) Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface. Immunopharmacology 38(1–2):119–127PubMedCrossRefGoogle Scholar
  63. Lindorfer M, Pawluczkowycz A, Peek E, Hickman K, Taylor R, Parker CJ (2010) A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 115(11):2283–2291PubMedCrossRefGoogle Scholar
  64. Logue GL (1977) Effect of heparin on complement activation and lysis of paroxysmal nocturnal hemoglobinuria (PNH) red cells. Blood 50(2):239–247PubMedGoogle Scholar
  65. Mahoney W, Hermodson M, Jones B, Powers D, Corfman R, Reeck G (1984) Amino acid sequence and secondary structural analysis of the corn inhibitor of trypsin and activated Hageman Factor. J Biol Chem 259(13):8412–8416PubMedGoogle Scholar
  66. Mangsbo SM, Sanchez J, Anger K, Lambris JD, Ekdahl KN, Loskog AS et al (2009) Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects. J Immunol 183(10):6724–6732PubMedCentralPubMedCrossRefGoogle Scholar
  67. Matsushita M, Thiel S, Jensenius J, Terai I, Fujita T (2000) Proteolytic activities of two types of mannose-binding ­lectin-associated serine protease. J Immunol 165:2637–2642PubMedCrossRefGoogle Scholar
  68. Moberg L, Johansson H, Luknius A, Berne C, Foss A, Källen R et al (2002) Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 360:2039–2045PubMedCrossRefGoogle Scholar
  69. Moberg L, Olsson A, Berne C, Felldin M, Foss A, Kallen R et al (2003) Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation 76(9):1285–1288PubMedCrossRefGoogle Scholar
  70. Moberg L, Korsgren O, Nilsson B (2005) Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin Exp Immunol 142(1):125–131PubMedCentralPubMedCrossRefGoogle Scholar
  71. Mollnes TE, Riesenfeld J, Garred P, Nordstrom E, Hogasen K, Fosse E et al (1995) A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif Organs 19(9):909–917PubMedCrossRefGoogle Scholar
  72. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G et al (2002) Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100(5):1869–1877PubMedGoogle Scholar
  73. Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A et al (1998) Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 92(5):1661–1667PubMedGoogle Scholar
  74. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD (2007) The role of complement in biomaterial-induced inflammation. Mol Immunol 44(1–3):82–94PubMedCrossRefGoogle Scholar
  75. Nilsson P, Engberg A, Bäck J, Faxälv L, Lindahl T, Nilsson B et al (2010) The creation of an antithrombotic surface by apyrase immobilization. Biomaterials 31(16):4484–4491PubMedCentralPubMedCrossRefGoogle Scholar
  76. Nilsson B, Nilsson Ekdahl K, Korsgren O (2011) Control of IBMIR (Instant Blood-Mediated Inflammatory Reaction) to improve islets of Langerhans engraftment. Curr Opin Organ Transplant 16(6):620–626PubMedCrossRefGoogle Scholar
  77. Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B (2002) Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 51(6):1779–1784PubMedCrossRefGoogle Scholar
  78. Patston P, Gettins P, Beechem J, Schapira M (1991) Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 30(36):8876–8882PubMedCrossRefGoogle Scholar
  79. Ratner BD (2007) The catastrophe revisited: blood compatibility in the 21st century. Biomaterials 28(34):5144–5147PubMedCentralPubMedCrossRefGoogle Scholar
  80. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P et al (2006) A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 177(7):4794–4802PubMedCrossRefGoogle Scholar
  81. Schousboe I, Nystrøm BT, Hansen GH (2008) Differential binding of factor XII and activated factor XII to soluble and immobilized fibronectin–localization of the Hep-1/Fib-1 binding site for activated factor XII. FEBS J 275(20):5161–5172PubMedCrossRefGoogle Scholar
  82. Selborn A, Andersson M, Fant C, Gretzer C, Elwing H (2003) Methods for research on immune complement activation on modified sensor surfaces. Colloids Surf B: Biointerfaces 27:295–301CrossRefGoogle Scholar
  83. Seyfert UT, Biehl V, Schenk J (2002) In vitro hemocompatibility testing of biomaterials according to the ISO 10993–4. Biomol Eng 19(2–6):91–96PubMedCrossRefGoogle Scholar
  84. Shankar R, de la Motte CA, Poptic EJ, DiCorleto PE (1994) Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem 269(19):13936–13941PubMedGoogle Scholar
  85. Sinn S, Scheuermann T, Deichelbohrer S, Ziemer G, Wendel HP (2011) A novel in vitro model for preclinical testing of the hemocompatibility of intravascular stents according to ISO 10993–4. J Mater Sci Mater Med 22(6):1521–1528PubMedCrossRefGoogle Scholar
  86. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE et al (2003) The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198(6):913–923PubMedCentralPubMedCrossRefGoogle Scholar
  87. Taylor F, Müller-Eberhard H (1970) Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets. J Clin Invest 49(1):2068–2085PubMedCentralPubMedCrossRefGoogle Scholar
  88. Tengvall P, Askendal A, Lundstrom I (2001) Ellipsometric in vitro studies on the activation of complement by human immunoglobulins M and G after adsorption to methylated silicon. Colloids Surf B: Biointerfaces 20(1):51–62PubMedCrossRefGoogle Scholar
  89. Thoman ML, Meuth JL, Morgan EL, Weigle WO, Hugli TE (1984) C3d-K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation. J Immunol 133(5):2629–2633PubMedGoogle Scholar
  90. Thor A, Rasmusson L, Wennerberg A, Thomsen P, Hirsch JM, Nilsson B et al (2007) The role of whole blood in thrombin generation in contact with various titanium surfaces. Biomaterials 28(6):966–974PubMedCrossRefGoogle Scholar
  91. Wettero J, Bengtsson T, Tengvall P (2001) C1q-independent activation of neutrophils by immunoglobulin M-coated surfaces. J Biomed Mater Res 57(4):550–558PubMedCrossRefGoogle Scholar
  92. Wouters D, Wiessenberg H, Hart M, Bruins P, Voskuyl A, Daha M et al (2005) Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation. J Immunol Methods 298:35–45PubMedCrossRefGoogle Scholar
  93. Wu Y, Simonovsky FI, Ratner BD, Horbett TA (2005) The role of adsorbed fibrinogen in platelet adhesion to polyurethane surfaces: a comparison of surface hydrophobicity, protein adsorption, monoclonal antibody binding, and platelet adhesion. J Biomed Mater Res A 74(4):722–738PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Kristina N. Ekdahl
    • 1
    • 2
  • Jaan Hong
    • 1
  • Osama A. Hamad
    • 1
  • Rolf Larsson
    • 1
    • 3
  • Bo Nilsson
    • 1
  1. 1.Department of Immunology, Genetics and Pathology, Rudbeck Laboratory C5:3Uppsala UniversityUppsalaSweden
  2. 2.School of Natural SciencesLinnæus UniversityKalmarSweden
  3. 3.Corline Systems ABUppsalaSweden

Personalised recommendations